Biomedical R&D needs a paradigm shift
Pharma and nutraceuticals:
Today, 50% of drugs fail in late stage development due to lack of superior efficacy,
at the same time costs still increase. That means the the current R&D model is broken.
Future new drugs can only be marketed if the right patient (the one that responds) is
identified and receives the right drug already during development.
Similarly, any health claim for functional food must be reflected by a documented
molecular mode of action and clinical correlate.
Industry and Research: There is no industry with a low productivity and ROI like the current biomedical R&D, both in industry and academia. This is primarily due to a lack of standardization. Consequently, standardization of methods must be included in the new Precision Medicine paradigm.
"The Cost Of Creating A New Drug (up to) $5 Billion US-$,
Pushing Big Pharma To Change"
Forbes, August 2013.
Pushing Big Pharma To Change"
Forbes, August 2013.
"‘You can’t make a business off this (contemporary R&D paradigm). This is not a good investment.’
I say that knowing that this has been the engine of wonderful things."
Susan Desmond-Hellmann, August 2013.
Patients and payers: Patients, patient organizations, and payers demand improved disease management ensuring better short- and long term outcome for chronic diseases.I say that knowing that this has been the engine of wonderful things."
Susan Desmond-Hellmann, August 2013.
Industry and Research: There is no industry with a low productivity and ROI like the current biomedical R&D, both in industry and academia. This is primarily due to a lack of standardization. Consequently, standardization of methods must be included in the new Precision Medicine paradigm.
The time is right
New ultrasensitive mass molecular diagnostics technologies
("*omics" such as genomics, proteomics, and metabolomics),
combined with Big Data analytics and machine learning,
have become cost-efficient with abundant proof of concept.
The convergence of these technologies allows the generation of new,
actionable insight into disease mechanisms.
This new knowledge is a necessary prerequisite for improved diagnostics, drug discovery and stratification, as well as functional food and nutraceutical discovery. Establishing business models within this convergence of technologies—the ability to digitize biology and increasing computing power—is a growing opportunity with disruptive potential well beyond for the biopharmaceutical and health care industry.
InnVentis well be at the verge of this trend, setting new standards in how health and disease are being managed.
This new knowledge is a necessary prerequisite for improved diagnostics, drug discovery and stratification, as well as functional food and nutraceutical discovery. Establishing business models within this convergence of technologies—the ability to digitize biology and increasing computing power—is a growing opportunity with disruptive potential well beyond for the biopharmaceutical and health care industry.
InnVentis well be at the verge of this trend, setting new standards in how health and disease are being managed.
Although grand in overall scope,
precision medicine can succeed iteratively
and likely can move forward only through pilot studies—
some that will establish standards and best practices
and some that will be scalable,
illuminating routes toward larger and broader efforts.
Science Translational Medicine Vol. 7, Issue 300, pp. 300ps17, 12 August 2015
precision medicine can succeed iteratively
and likely can move forward only through pilot studies—
some that will establish standards and best practices
and some that will be scalable,
illuminating routes toward larger and broader efforts.
Science Translational Medicine Vol. 7, Issue 300, pp. 300ps17, 12 August 2015